34.57
price down icon5.75%   -2.11
after-market 시간 외 거래: 34.83 0.26 +0.75%
loading
전일 마감가:
$36.68
열려 있는:
$35.8
하루 거래량:
2.94M
Relative Volume:
1.15
시가총액:
$10.05B
수익:
$2.08B
순이익/손실:
$466.92M
주가수익비율:
22.16
EPS:
1.56
순현금흐름:
$404.94M
1주 성능:
-5.80%
1개월 성능:
-9.72%
6개월 성능:
+29.67%
1년 성능:
+47.17%
1일 변동 폭
Value
$34.48
$36.45
1주일 범위
Value
$34.48
$37.18
52주 변동 폭
Value
$20.14
$40.02

Exelixis Inc Stock (EXEL) Company Profile

Name
명칭
Exelixis Inc
Name
전화
(650) 837-7000
Name
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Name
직원
1,147
Name
트위터
@exelixisinc
Name
다음 수익 날짜
2025-02-11
Name
최신 SEC 제출 서류
Name
EXEL's Discussions on Twitter

EXEL을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
EXEL
Exelixis Inc
34.57 10.05B 2.08B 466.92M 404.94M 1.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 125.40B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 65.79B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 35.18B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 32.67B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 26.46B 3.81B -644.79M -669.77M -6.24

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-24 다운그레이드 Wells Fargo Overweight → Equal Weight
2025-01-27 업그레이드 Morgan Stanley Equal-Weight → Overweight
2025-01-24 다운그레이드 Oppenheimer Outperform → Perform
2024-12-20 다운그레이드 BMO Capital Markets Outperform → Market Perform
2024-12-17 다운그레이드 BofA Securities Buy → Neutral
2024-10-16 재확인 RBC Capital Mkts Outperform
2024-09-19 개시 UBS Neutral
2024-04-11 다운그레이드 Barclays Overweight → Equal Weight
2023-12-19 개시 BTIG Research Buy
2023-12-15 개시 Citigroup Buy
2023-09-26 개시 H.C. Wainwright Buy
2023-08-22 재확인 Oppenheimer Outperform
2023-08-08 개시 SVB Securities Market Perform
2023-07-11 재개 Morgan Stanley Equal-Weight
2023-05-10 재개 Piper Sandler Overweight
2023-03-09 개시 Wells Fargo Overweight
2023-01-26 개시 Credit Suisse Outperform
2022-10-18 개시 JMP Securities Mkt Outperform
2022-06-24 개시 BMO Capital Markets Outperform
2021-11-19 개시 Piper Sandler Overweight
2021-11-03 재개 Jefferies Buy
2021-10-07 개시 Jefferies Buy
2021-08-06 재확인 H.C. Wainwright Buy
2021-06-15 개시 H.C. Wainwright Buy
2021-05-18 재개 Goldman Sell
2021-03-31 개시 Credit Suisse Outperform
2021-03-12 개시 Wolfe Research Outperform
2020-03-04 개시 Barclays Overweight
2020-01-13 개시 SunTrust Buy
2019-11-13 개시 BofA/Merrill Buy
2019-03-18 업그레이드 Morgan Stanley Underweight → Equal-Weight
2018-09-17 개시 Goldman Neutral
2018-09-10 개시 Morgan Stanley Underweight
2018-05-11 재확인 Needham Buy
2017-10-17 재확인 Needham Buy
2017-10-17 재확인 RBC Capital Mkts Outperform
2017-10-16 재확인 SunTrust Buy
2017-09-22 다운그레이드 Leerink Partners Outperform → Mkt Perform
2017-09-15 개시 RBC Capital Mkts Outperform
2017-09-12 재확인 Needham Buy
2017-07-14 개시 SunTrust Buy
2017-03-31 개시 Needham Buy
2017-03-16 개시 Oppenheimer Perform
2017-02-28 다운그레이드 Stifel Buy → Hold
2016-11-03 개시 Deutsche Bank Buy
2016-10-10 업그레이드 Piper Jaffray Neutral → Overweight
2016-09-15 재확인 Stifel Buy
모두보기

Exelixis Inc 주식(EXEL)의 최신 뉴스

pulisher
Apr 03, 2025

The Smartest Biotech Stocks to Buy With $50 - The Motley Fool

Apr 03, 2025
pulisher
Apr 03, 2025

FY2026 EPS Estimates for Exelixis Lifted by Leerink Partnrs - MarketBeat

Apr 03, 2025
pulisher
Apr 02, 2025

Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now? - Insider Monkey

Apr 02, 2025
pulisher
Apr 02, 2025

Trexquant Investment LP Has $19.82 Million Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Blair William & Co. IL Sells 300,760 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Apr 02, 2025
pulisher
Apr 01, 2025

New Age Alpha Advisors LLC Makes New $2.10 Million Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Apr 01, 2025
pulisher
Mar 31, 2025

Exelixis Launches Special Equity Award Program - TipRanks

Mar 31, 2025
pulisher
Mar 30, 2025

(EXEL) Long Term Investment Analysis - news.stocktradersdaily.com

Mar 30, 2025
pulisher
Mar 29, 2025

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors - MSN

Mar 29, 2025
pulisher
Mar 29, 2025

What is Leerink Partnrs' Estimate for Exelixis Q1 Earnings? - MarketBeat

Mar 29, 2025
pulisher
Mar 28, 2025

Exelixis gets FDA nod for its advanced neuroendocrine tumor treatment - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Exelixis stock holds $40 target post FDA nod By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 27, 2025

FDA Expands Exelixis Cabometyx Label For Neuroendocrine Tumors - Barchart.com

Mar 27, 2025
pulisher
Mar 27, 2025

Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL) - The Globe and Mail

Mar 27, 2025
pulisher
Mar 27, 2025

Exelixis stock holds $40 target post FDA nod - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Stifel maintains Exelixis stock hold, $36 target post FDA nod By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 26, 2025

FDA approves new treatment for advanced neuroendocrine tumors By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis to present positive preclinical data across pipeline portfolio at AACR - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Leerink lifts Exelixis stock target to $33 post FDA approval By Investing.com - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold? - TradingView

Mar 26, 2025
pulisher
Mar 26, 2025

Leerink lifts Exelixis stock target to $33 post FDA approval - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Stifel maintains Exelixis stock hold, $36 target post FDA nod - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis’ primary cancer drug wins FDA approval for neuroendocrine tumors - Endpoints News

Mar 26, 2025
pulisher
Mar 26, 2025

FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Citi maintains Buy on Exelixis stock with $45 target By Investing.com - Investing.com Canada

Mar 26, 2025
pulisher
Mar 26, 2025

Citi maintains Buy on Exelixis stock with $45 target - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis' cancer drug gets FDA approval but analysts say its priced in; shares down - TradingView

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis wins FDA label expansion for Cabometyx (EXEL:NASDAQ) - Seeking Alpha

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis Gets FDA Approval for Drug Treating Patients With Previously Treated Advanced Neuroendocrine Tumors - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis Gets Expanded FDA Approval of Cabometyx in Advanced Neuroendocrine Tumors - MarketWatch

Mar 26, 2025
pulisher
Mar 26, 2025

Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis Announces U.S. FDA Approval Of CABOMETYX® (cabozantinib) For Patients With Previously Treated Advanced Neuroendocrine Tumors - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

FDA approves new treatment for advanced neuroendocrine tumors - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Joplin Globe

Mar 26, 2025
pulisher
Mar 26, 2025

(cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire

Mar 26, 2025
pulisher
Mar 26, 2025

FDA Approves Cabozantinib For Adults And Pediatric Patients 12 Years Of Age And Older With pNET And epNET - MarketScreener

Mar 26, 2025
pulisher
Mar 25, 2025

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025 - BioSpace

Mar 25, 2025
pulisher
Mar 25, 2025

Looking Into Exelixis's Recent Short Interest - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

Exelixis (NASDAQ:EXEL) shareholders have earned a 16% CAGR over the last five years - simplywall.st

Mar 25, 2025
pulisher
Mar 24, 2025

Biotech Leader Exelixis Eyes Buy Point In Today's Stock Market Rally - MSN

Mar 24, 2025
pulisher
Mar 21, 2025

Interesting EXEL Put And Call Options For November 21st - Nasdaq

Mar 21, 2025
pulisher
Mar 20, 2025

Learn to Evaluate (EXEL) using the Charts - Stock Traders Daily

Mar 20, 2025
pulisher
Mar 20, 2025

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance

Mar 20, 2025
pulisher
Mar 19, 2025

Exelixis Growth Continues with Big Money Boosts - Yahoo Finance

Mar 19, 2025
pulisher
Mar 18, 2025

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA - Business Wire

Mar 18, 2025
pulisher
Mar 18, 2025

Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance

Mar 18, 2025

Exelixis Inc (EXEL) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$60.26
price down icon 10.70%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
자본화:     |  볼륨(24시간):